glp-1 receptor agonists
The Day Semaglutide Lost to Tirzepatide's Dual Key
The Day Semaglutide Lost to Tirzepatide's Dual Key In 2023, tirzepatide achieved up to 22% weight loss in the SURMOUNT-1 study, showing it outperforms semaglutide because it activates both GLP-1 and GIP receptors. This dual-key mechanism explains the larger appetite-suppression and insulin-sensitizing effects observed in real-world practice. Medical